{"id":32496,"date":"2025-06-17T17:21:36","date_gmt":"2025-06-17T11:51:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32496"},"modified":"2026-01-30T13:11:11","modified_gmt":"2026-01-30T07:41:11","slug":"pharma-news-for-celltrion-csl-ocugen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen","title":{"rendered":"Celltrion Announces FDA Nod for New STEQEYMA Presentation to Broaden Pediatric Use; CSL\u2019s ANDEMBRY Gets FDA Nod as First Factor XIIa Inhibitor for Hereditary Angioedema; Ocugen\u2019s OCU410ST Cleared by FDA to Begin Phase II\/III Trial in Stargardt Disease; Milestone Pharmaceuticals Submits FDA Response for CARDAMYST in PSVT; AbbVie\u2019s MAVYRET Approved by FDA as First and Only Therapy for Acute Hepatitis C"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07bd950fbdf\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07bd950fbdf\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\/#Celltrion_Announces_FDA_Approval_of_New_STEQEYMA_Presentation_Expanding_Pediatric_Dosing_Options\" >Celltrion Announces FDA Approval of New STEQEYMA Presentation, Expanding Pediatric Dosing Options<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\/#FDA_Approves_CSLs_ANDEMBRY_as_First_Factor_XIIa_Inhibitor_for_Hereditary_Angioedema\" >FDA Approves CSL\u2019s ANDEMBRY as First Factor XIIa Inhibitor for Hereditary Angioedema<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\/#Ocugen_Gets_FDA_Clearance_to_Begin_Phase_IIIII_Trial_of_OCU410ST_for_Stargardt_Disease\" >Ocugen Gets FDA Clearance to Begin Phase II\/III Trial of OCU410ST for Stargardt Disease<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\/#Milestone_Pharmaceuticals_Submits_FDA_Response_on_CARDAMYST_for_PSVT\" >Milestone Pharmaceuticals Submits FDA Response on CARDAMYST for PSVT<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\/#FDA_Approves_AbbVies_MAVYRET_as_First_and_Only_Treatment_for_Acute_Hepatitis_C\" >FDA Approves AbbVie&#8217;s MAVYRET as First and Only Treatment for Acute Hepatitis C<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-celltrion-announces-fda-approval-of-new-steqeyma-presentation-expanding-pediatric-dosing-options\"><span class=\"ez-toc-section\" id=\"Celltrion_Announces_FDA_Approval_of_New_STEQEYMA_Presentation_Expanding_Pediatric_Dosing_Options\"><\/span>Celltrion Announces FDA Approval of New STEQEYMA Presentation, Expanding Pediatric Dosing Options<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Celltrion, Inc.<\/strong> has announced that the <strong>FDA has approved<\/strong> an additional presentation of <em>STEQEYMA<\/em> (ustekinumab-stba), a biosimilar to <em>STELARA<\/em>, in a 45mg\/0.5mL single-dose vial for <strong>subcutaneous injection<\/strong>. This new formulation is now indicated for pediatric patients aged 6 to 17 years weighing under 60kg with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\" class=\"ek-link\">p<\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\" class=\"ek-link\"><strong>laque psoriasis (PsO)<\/strong><\/a><strong> <\/strong>or <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\" class=\"ek-link\"><strong>psoriatic arthritis (PsA)<\/strong><\/a>. With this approval, STEQEYMA now mirrors all dosage forms and strengths of its reference product, STELARA, expanding treatment flexibility and continuity for younger patient populations.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe new dosage form and strength of STEQEYMA allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile,\u201d said Hetal Patel, PharmD MBA, Vice President of Medical Affairs at Celltrion USA.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Celltrion had previously received FDA approval in December 2024 for other formulations of STEQEYMA, including 45mg\/0.5mL and 90mg\/mL in single-dose prefilled syringes for subcutaneous injection, and 130mg\/26mL in a single-dose vial for intravenous infusion. These were approved for both adult and pediatric patients aged 6 and above with PsO and PsA, and for adults with Crohn\u2019s disease and ulcerative colitis.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis approval reinforces our commitment to broadening access for all patient populations, including children aged 6 years and older living with chronic inflammatory conditions,\u201d added Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. \u201cAs a company with a strong legacy in immunology, we are dedicated to ensuring broader access and flexibility in care for patients of all ages.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval was supported by robust Phase III clinical data, which confirmed biosimilarity between STEQEYMA and STELARA in terms of efficacy, safety, and immunogenicity. The FDA has also granted STEQEYMA full interchangeability with STELARA across all approved indications, following the expiration of exclusivity for the first interchangeable biosimilar in April 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-csl-s-andembry-as-first-factor-xiia-inhibitor-for-hereditary-angioedema\"><span class=\"ez-toc-section\" id=\"FDA_Approves_CSLs_ANDEMBRY_as_First_Factor_XIIa_Inhibitor_for_Hereditary_Angioedema\"><\/span>FDA Approves CSL\u2019s ANDEMBRY as First Factor XIIa Inhibitor for Hereditary Angioedema<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>CSL has announced <\/strong>that the<strong> FDA has approved <em>ANDEMBRY<\/em> (garadacimab-gxii),<\/strong> making it the <strong>first and only<\/strong> prophylactic treatment for <strong><em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-angioedema-market\">hereditary angioedema<\/a><\/em><\/strong> that targets<strong> <em>Factor XIIa<\/em>. <\/strong>The once-monthly subcutaneous therapy is approved for use in both adult and pediatric patients aged 12 and older, offering rapid, self-administered protection from HAE attacks with a citrate-free formula delivered in 15 seconds or less via autoinjector.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;ANDEMBRY, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method,\u201d said Dr. Bill Mezzanotte, Executive VP and Head of R&amp;D at CSL. \u201cThis approval reflects CSL\u2019s enduring commitment to addressing unmet needs in rare disease communities, including those living with HAE.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s approval was based on results from the pivotal Phase III VANGUARD trial published in <em>The Lancet (April 2023)<\/em>. The study showed ANDEMBRY reduced HAE attacks by a <em>median of over 99%<\/em> and a <em>least squares mean of 89.2%<\/em> compared to placebo. Additionally, 62% of patients treated with ANDEMBRY remained attack-free during the treatment period. The therapy also significantly reduced moderate-to-severe attacks and the need for on-demand rescue medication. Safety data from the ongoing open-label extension study reaffirmed its favorable long-term safety profile, with injection-site reactions and mild adverse events such as nasopharyngitis being the most common.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cMany patients with HAE still face the burden of painful, life-threatening attacks and frequent injections,\u201d said Dr. Tim Craig, Professor at Penn State University. \u201cANDEMBRY introduces a novel approach by inhibiting Factor XIIa, the top of the HAE cascade, which is a meaningful advance in how we manage this condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Anthony J. Castaldo, CEO of the US HAE Association and HAE International, added, \u201cA once-monthly subcutaneous therapy like ANDEMBRY provides our community with greater freedom and the opportunity to live life more fully.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s nod follows recent approvals of ANDEMBRY in Australia, the UK, EU, Japan, Switzerland, and the UAE, signaling a major global expansion of CSL\u2019s HAE portfolio and the company\u2019s continued leadership in rare immunological conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ocugen-gets-fda-clearance-to-begin-phase-ii-iii-trial-of-ocu410st-for-stargardt-disease\"><span class=\"ez-toc-section\" id=\"Ocugen_Gets_FDA_Clearance_to_Begin_Phase_IIIII_Trial_of_OCU410ST_for_Stargardt_Disease\"><\/span>Ocugen Gets FDA Clearance to Begin Phase II\/III Trial of OCU410ST for Stargardt Disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ocugen, Inc. <\/strong>has announced <strong>FDA clearance<\/strong> of its<strong> Investigational New Drug (IND)<\/strong> amendment to initiate a pivotal Phase II\/III confirmatory trial of <em>OCU410ST<\/em>, a modifier gene therapy candidate developed for <a href=\"https:\/\/www.delveinsight.com\/report-store\/stargardt-disease-stgd-market\" class=\"ek-link\"><strong><em>S<\/em><\/strong><\/a><strong><em><a href=\"https:\/\/www.delveinsight.com\/report-store\/stargardt-disease-stgd-market\" class=\"ek-link\">targardt<\/a><\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/stargardt-disease-stgd-market\" class=\"ek-link\"><strong><em> disease<\/em><\/strong><\/a><strong> <\/strong>and other ABCA4-associated retinopathies. The announcement follows the therapy\u2019s Rare Pediatric Disease and Orphan Drug designations, reinforcing OCU410ST\u2019s potential for treating rare, inherited retinal conditions for which no approved treatments currently exist.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe\u2019ve had a highly productive engagement with the FDA\u2019s Center for Biologics Evaluation and Research,\u201d said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. \u201cThere is a visible sense of urgency from the agency in getting treatments to patients with no current options. With this clearance, we\u2019re able to accelerate clinical development of OCU410ST by two to three years, bringing hope to those affected by this devastating condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Positive data from Ocugen\u2019s Phase I <em>GARDian<\/em> trial showed a favorable safety profile and promising efficacy signals, including a statistically significant two-line improvement in best corrected visual acuity (BCVA) and a 48% slower lesion growth at 12 months in treated eyes versus untreated controls. The new Phase II\/III trial will enroll 51 patients with Stargardt disease, assigning 34 to receive a one-time subretinal injection of OCU410ST and 17 to a control group. The primary endpoint will focus on reduction in atrophic lesion size, while secondary endpoints include improvements in BCVA and low luminance visual acuity (LLVA).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe launch of this pivotal trial marks a critical step in advancing our mission to deliver life-changing genetic therapies,\u201d said Dr. Huma Qamar, Ocugen\u2019s Chief Medical Officer. \u201cOCU410ST, developed through our proprietary modifier gene therapy platform, aims to address the disease at its root, offering hope for lasting impact in pediatric and adult patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>With approximately 1 million people worldwide affected by Stargardt disease and ABCA4 retinopathies, the trial addresses a significant unmet need. \u201cThis study is scientifically robust and patient-centered,\u201d said Dr. Lejla Vajzovic, Professor of Ophthalmology at Duke University. \u201cWe\u2019re hopeful it will bring us closer to an effective therapy for children and young adults battling this progressive condition.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Ocugen plans to submit a Biologics License Application (BLA) for OCU410ST in 2027, aligning with its roadmap to file three BLAs over the next three years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-milestone-pharmaceuticals-submits-fda-response-on-cardamyst-for-psvt\"><span class=\"ez-toc-section\" id=\"Milestone_Pharmaceuticals_Submits_FDA_Response_on_CARDAMYST_for_PSVT\"><\/span>Milestone Pharmaceuticals Submits FDA Response on CARDAMYST for PSVT<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Milestone Pharmaceuticals <\/strong>has submitted its formal response to the <strong>FDA <\/strong>addressing the<strong> Complete Response Letter (CRL) <\/strong>for its <strong>New Drug Application (NDA) <\/strong>for <strong><em>CARDAMYST<\/em> (etripamil)<\/strong>, a nasal spray intended for the acute treatment of <strong><em><a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-supraventricular-tachycardia-market\" class=\"ek-link\">paroxysmal s<\/a><\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-supraventricular-tachycardia-market\" class=\"ek-link\"><strong><em>upraventricular tachycardia<\/em> (PSVT)<\/strong><\/a> in adults. The submission follows a productive Type A meeting with the FDA, during which the agency provided guidance enabling Milestone to promptly finalize and file its response.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe appreciate the constructive dialogue with the FDA and the clarity provided during our recent Type A meeting,\u201d said Joe Oliveto, President and CEO of Milestone Pharmaceuticals. \u201cWith this resubmission, we are optimistic about a potential PDUFA date later this year and the opportunity to deliver CARDAMYST to patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>If approved, <em>CARDAMYST<\/em> would become the first and only <em>self-administered treatment<\/em> for the rapid resolution of PSVT episodes\u2014a breakthrough for patients who currently rely on emergency room visits or intravenous therapies. The company expects the FDA to determine the acceptance and classification of the response within 30 days, setting the stage for a review period of either two or six months.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-abbvie-s-mavyret-as-first-and-only-treatment-for-acute-hepatitis-c\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AbbVies_MAVYRET_as_First_and_Only_Treatment_for_Acute_Hepatitis_C\"><\/span>FDA Approves AbbVie&#8217;s MAVYRET as First and Only Treatment for Acute Hepatitis C<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AbbVie <\/strong>has announced that the <strong>FDA <\/strong>has approved a major label expansion for <strong><em>MAVYRET <\/em>(glecaprevir\/pibrentasvir), <\/strong>making it the first and only direct-acting antiviral (DAA) therapy approved for treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-c-virus-market\" class=\"ek-link\"><strong><em>acute <\/em><\/strong><\/a><strong><em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-c-virus-market\" class=\"ek-link\">hepa<\/a><\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-c-virus-market\" class=\"ek-link\"><strong><em>titis C virus (HCV)<\/em><\/strong><\/a><strong> <\/strong>in both adults and pediatric patients aged three years and older. The once-daily oral treatment, previously indicated for chronic HCV, can now be prescribed for acute cases, offering an 8-week regimen with a 96% cure rate.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cMAVYRET has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection,\u201d said Roopal Thakkar, M.D., Executive Vice President, R&amp;D and Chief Scientific Officer at AbbVie. \u201cThis label expansion, combined with test-and-treat models of care, helps support broader access to treatment and brings us closer to achieving the global hepatitis C elimination goals.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Acute HCV often presents without symptoms and, if untreated, may lead to serious complications such as cirrhosis and liver cancer. The U.S. alone is projected to face over $120 billion in medical costs by 2035 due to untreated chronic liver conditions. By enabling earlier intervention, MAVYRET could significantly reduce this burden.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe physical, emotional, and economic burden of a curable condition like hepatitis C is far too great,\u201d added Dr. John Ward, Director of the Coalition for Global Hepatitis Elimination. \u201cWith safe, effective therapies like MAVYRET now available for early-stage treatment, we can stop hepatitis C before it becomes a deadly, chronic disease. No one should die from hepatitis C.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA\u2019s decision was supported by results from a Phase III, multicenter study evaluating MAVYRET in acute HCV patients, where the majority of adverse events were mild to moderate. The approval follows <em>Breakthrough Therapy Designation<\/em> granted to MAVYRET, recognizing its potential to significantly improve care for patients with serious viral infections.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celltrion Announces FDA Approval of New STEQEYMA Presentation, Expanding Pediatric Dosing Options Celltrion, Inc. has announced that the FDA has approved an additional presentation of STEQEYMA (ustekinumab-stba), a biosimilar to STELARA, in a 45mg\/0.5mL single-dose vial for subcutaneous injection. This new formulation is now indicated for pediatric patients aged 6 to 17 years weighing under [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32497,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[204,704,1394,17471,964,1270,21855,349,420,639,1546,20562,20560,19047,19878,19876,19877,5789,1298],"industry":[17225],"therapeutic_areas":[17242,17237,17238,17227,17231,17244],"class_list":["post-32496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight","tag-fda","tag-hepatitis-c","tag-hepatitis-c-drugs","tag-hepatitis-c-infection","tag-hereditary-angioedema","tag-hereditary-angioedema-market","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-plaque-psoriasis","tag-plaque-psoriasis-drugs","tag-plaque-psoriasis-treatment","tag-psoriatic-arthritis","tag-psoriatic-arthritis-drugs","tag-psoriatic-arthritis-treatment","tag-psoriatic-arthritis-treatment-market","tag-recent-pharma-news","tag-stargardt-disease","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-dermatology","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Celltrion, CSL, Ocugen<\/title>\n<meta name=\"description\" content=\"Celltrion\u2019s STEQEYMA; CSL\u2019s ANDEMBRY; Ocugen\u2019s OCU410ST; Milestone\u2019s CARDAMYST; AbbVie\u2019s MAVYRET for Acute Hepatitis C\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Celltrion, CSL, Ocugen\" \/>\n<meta property=\"og:description\" content=\"Celltrion\u2019s STEQEYMA; CSL\u2019s ANDEMBRY; Ocugen\u2019s OCU410ST; Milestone\u2019s CARDAMYST; AbbVie\u2019s MAVYRET for Acute Hepatitis C\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-17T11:51:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T07:41:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Celltrion, CSL, Ocugen","description":"Celltrion\u2019s STEQEYMA; CSL\u2019s ANDEMBRY; Ocugen\u2019s OCU410ST; Milestone\u2019s CARDAMYST; AbbVie\u2019s MAVYRET for Acute Hepatitis C","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Celltrion, CSL, Ocugen","og_description":"Celltrion\u2019s STEQEYMA; CSL\u2019s ANDEMBRY; Ocugen\u2019s OCU410ST; Milestone\u2019s CARDAMYST; AbbVie\u2019s MAVYRET for Acute Hepatitis C","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-17T11:51:36+00:00","article_modified_time":"2026-01-30T07:41:11+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen","name":"Pharma News | Celltrion, CSL, Ocugen","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature.png","datePublished":"2025-06-17T11:51:36+00:00","dateModified":"2026-01-30T07:41:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Celltrion\u2019s STEQEYMA; CSL\u2019s ANDEMBRY; Ocugen\u2019s OCU410ST; Milestone\u2019s CARDAMYST; AbbVie\u2019s MAVYRET for Acute Hepatitis C","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-celltrion-csl-ocugen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature.png","width":772,"height":482,"caption":"pharma-news-for-celltrion-csl-ocugen"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/17172120\/17-06-2025-feature-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis c<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatitis C Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatitis C Infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hereditary Angioedema<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hereditary Angioedema Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque psoriasis drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Psoriatic Arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">psoriatic arthritis drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">psoriatic arthritis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">psoriatic arthritis treatment market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stargardt Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">hepatitis c<\/span>","<span class=\"advgb-post-tax-term\">Hepatitis C Drugs<\/span>","<span class=\"advgb-post-tax-term\">Hepatitis C Infection<\/span>","<span class=\"advgb-post-tax-term\">Hereditary Angioedema<\/span>","<span class=\"advgb-post-tax-term\">Hereditary Angioedema Market<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Plaque psoriasis drugs<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis treatment<\/span>","<span class=\"advgb-post-tax-term\">Psoriatic Arthritis<\/span>","<span class=\"advgb-post-tax-term\">psoriatic arthritis drugs<\/span>","<span class=\"advgb-post-tax-term\">psoriatic arthritis treatment<\/span>","<span class=\"advgb-post-tax-term\">psoriatic arthritis treatment market<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Stargardt Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 4 months ago"},"absolute_dates":{"created":"Posted on Jun 17, 2025","modified":"Updated on Jan 30, 2026"},"absolute_dates_time":{"created":"Posted on Jun 17, 2025 5:21 pm","modified":"Updated on Jan 30, 2026 1:11 pm"},"featured_img_caption":"pharma-news-for-celltrion-csl-ocugen\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32496"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32496\/revisions"}],"predecessor-version":[{"id":34421,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32496\/revisions\/34421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32497"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32496"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32496"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}